drugmaker

Pharmaceutical giant Allergan struck a bold and unusual deal to protect its patents on a lucrative eye drug in September.

Eli Lilly has dropped a lower-than-expected 2016 forecast on Wall Street after wrapping up a year in which its stock soared above the broader market